论文部分内容阅读
目的:探讨肺癌患者血清中可溶性MICA(sMICA)的表达及临床意义。方法:选取30例肺癌患者作为试验组,30例健康志愿者作为对照组,利用ELISA法测定两组患者血清中sMICA分子表达值,对其结果进行分析。结果:试验组与对照组比较,肺癌患者血清sMICA分子测定值高表达,健康组呈低表达,二者比较差异有显著性(P<0.01)。结论:肺癌患者血清中sMICA分子测定值高表达,MICA的可溶性(sMICA)表达可能是导致肿瘤细胞发生免疫逃逸的原因之一。sMICA血清水平的测定可能成为预测肺癌患者免疫功能状态及肿瘤恶性转移的免疫诊断指标之一。
Objective: To investigate the expression and clinical significance of serum soluble MICA (sMICA) in patients with lung cancer. Methods: Thirty patients with lung cancer were selected as experimental group and 30 healthy volunteers as control group. The expression of sMICA in sera of two groups of patients was determined by ELISA, and the results were analyzed. Results: Compared with the control group, the serum level of sMICA in lung cancer patients was significantly higher than that in the control group, while it was lower in the healthy group. There was significant difference between the two groups (P <0.01). CONCLUSIONS: The high expression of sMICA in serum of patients with lung cancer and the expression of soluble MICA (sMICA) may be one of the reasons leading to immune escape in tumor cells. The determination of sMICA serum levels may become one of the immune diagnostic indicators for predicting the immune status of patients with lung cancer and malignant tumor metastasis.